Ainos Enters License Agreement with BioPhoenix for Up to $10M in Conditional Consideration
Ainos (AIMD) has signed a licensing agreement with BioPhoenix Co. granting the latter exclusive worldwide rights to develop and commercialize VELDONA, Ainos' low-dose oral interferon alpha platform, for two initial indications: Sjögren's disease and thrombocytopenia. The deal outlines up to $10 million in conditional consideration tied to specific development milestones. BioPhoenix will lead the clinical development of these indications under the licensing framework. This partnership marks a significant step forward for VELDONA, which has shown potential across multiple therapeutic areas due to its novel delivery mechanism and reduced side-effect profile. The agreement reflects growing interest from biopharma companies in Ainos' platform technology and could accelerate the clinical development of interferon-based therapies with improved patient outcomes.
Tickers: $AIMD